AbbVie to acquire Cerevel Therapeutics for $8.7bn
Emraclidine is a late-stage antipsychotic asset of Cerevel being analysed for the treatment of schizophrenia.

Emraclidine is a late-stage antipsychotic asset of Cerevel being analysed for the treatment of schizophrenia.
The updated Covid-19 vaccine is also authorised for use in the US and the European Union.
The pharmaceutical industry continues to be a hotbed of patent innovation. Activity is driven by the evolution of treatment paradigms,...
MSD reinforces Amazon partnership for faster AI-led drug discovery and development
Japan grants approval for CSL and Arcturus’ Covid-19 vaccine
Boehringer to leverage IBM’s technologies for antibody discovery
Japan approves Daiichi Sankyo’s Covid-19 booster vaccine